Praxis Precision Medicines Prices $575 Million Public Offering at $260 Per Share—What Does This Mean for Its Future?
Market Chameleon (Wed, 7-Jan 9:24 AM)
FDA Grants Breakthrough Therapy Designation to Praxis’ Ulixacaltamide for Essential Tremor After Positive Phase 3 Data
Market Chameleon (Mon, 29-Dec 8:40 AM)
Praxis' EMBOLD Study Achieves Early Success—Positive Results for Relutrigine in Rare Epilepsies Spur FDA Meeting
Market Chameleon (Fri, 5-Dec 10:29 AM)
